Reducing Protocol Deviations in IRD Ophthalmology Trials Through Criticality Checklists and Escalation Pathways
The American Journal of Medical Sciences and Pharmaceutical Research · 14.08.2026 · 08 (08) · 21-37
DOI: 10.37547/tajmspr/volume08issue08-03 ↗Kurz gefasst
Studienprotokoll in der Zeitschrift The American Journal of Medical Sciences and Pharmaceutical Research, online erschienen am 14.08.2026. Verfasst von Santosh R. Tarode.
Abstract (Originalsprache)
Protocol deviations in inherited retinal disease (IRD) ophthalmology trials represent a multifaceted operational challenge threatening participant safety and primary endpoint data integrity (Getz, 2011; Cilley, 2025). These deviations span imaging acquisition, functional testing, investigational product handling, and visit scheduling. Unlike conventional pharmacological trials, IRD gene therapy involves irreversible surgical interventions where deviations cannot be recovered through repeat visits (Russell, 2017). This article presents a comprehensive framework for classifying protocol deviation types in IRD trials and identifies strategic intervention points enabling proactive prevention through structured pre-visit preparation and real-time escalation protocols. The Procedure Criticality Checklist (PCC) system applies risk-based monitoring principles (International Council for Harmonization, 2023) by severity and implementing targeted prevention mechanisms. The framework integrates evidence from surgical safety science (Haynes, 2009), quality-by-design methodology (TransCelerate Biopharma, 2023), IRD trial operations literature (Thompson, 2020). The framework comprises: (1) a deviation taxonomy, (2) criticality-stratified pre-visit checklists, (3) tiered escalation pathways with predefined decision authorities, and (4) electronic integration mechanisms real-time monitoring. Implementation is anticipated to reduce preventable deviations, improve data integrity, strengthen regulatory submissions, and accelerate approval timelines for ATMP ophthalmology programs. This framework addresses a critical gap in IRD trial operations by providing standardized, operationalizable deviation prevention methodology suitable for adoption across national research networks (Igoe, 2024).
Zitieren
APA
Tarode, S. R. (2026). Reducing Protocol Deviations in IRD Ophthalmology Trials Through Criticality Checklists and Escalation Pathways. The American Journal of Medical Sciences and Pharmaceutical Research, 08(08), 21-37. https://doi.org/10.37547/tajmspr/volume08issue08-03
Vancouver
Tarode SR. Reducing Protocol Deviations in IRD Ophthalmology Trials Through Criticality Checklists and Escalation Pathways. The American Journal of Medical Sciences and Pharmaceutical Research. 2026;08(08):21-37. doi:10.37547/tajmspr/volume08issue08-03
BibTeX
@article{Tarode2026,
author = {Tarode, Santosh R.},
title = {Reducing Protocol Deviations in IRD Ophthalmology Trials Through Criticality Checklists and Escalation Pathways},
journal = {The American Journal of Medical Sciences and Pharmaceutical Research},
year = {2026},
volume = {08},
number = {08},
pages = {21--37},
doi = {10.37547/tajmspr/volume08issue08-03}
}
EUVIMED